Tyler J Wildes1, Adam Grippin2, Henrietta Fasanya3, Kyle A Dyson2, Mark Brantly4. 1. University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA; University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, USA. Electronic address: twildes@ufl.edu. 2. University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA; University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy, Lillian S. Wells Department of Neurosurgery, McKnight Brain Institute, University of Florida, Gainesville, FL, USA. 3. University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA; University of Florida Health Cancer Center, Department of Radiation Oncology, Gainesville, FL, USA. 4. University of Florida MD-PhD Program, College of Medicine, Gainesville, FL, USA; University of Florida Division of Pulmonary and Critical Care Medicine, Gainesville, FL, USA.
Abstract
BACKGROUND: The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination. METHODS: Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis. RESULTS: Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177). CONCLUSIONS:Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02097589.
RCT Entities:
BACKGROUND: The immunomodulatory effects of statins on vaccine response remain uncertain. Therefore, the objective of this study was to determine if atorvastatin enhances pneumococcal-specific antibody titer following 23-valent pneumococcal polysaccharide vaccination. METHODS: Double-blind, placebo-controlled, single-center randomized clinical trial entitled StatVax. Subjects were enrolled between June and July 2014 and followed up through September 2014. 33 healthy volunteers signed informed consent after volunteer sampling. 11 participants were excluded; 22 healthy volunteers without prior pneumococcal vaccination were enrolled and completed the study. Participants were randomized to receive a 28-day course of 40 mg atorvastatin (n = 12) or matching lactose placebo (n = 10). On day 7 of treatment, Pneumovax 23 was administered intramuscularly. The primary outcome was fold change in total pneumococcal-specific antibody titer determined by a ratio of post-vaccination titer over baseline titer. Secondary outcomes included serotype-specific pneumococcal antibody titer, seroconversion, complete blood counts (CBC), erythrocyte sedimentation rate (ESR), and serum cytokine analysis. RESULTS: Of the 22 randomized patients (mean age, 23.86; SD, 4.121; 11 women [50%]), 22 completed the trial. Total anti-pneumococcal antibody titer in the atorvastatin group went from a baseline mean of 32.58 (SD, 15.96) to 147.7 (SD, 71.52) μg/mL at 21 days post-vaccination while titer in the placebo group went from a mean of 30.81 (SD, 13.04) to 104.4 (SD, 45) μg/mL. When comparing fold change between treatment groups, there was a significant increase in fold change of total anti-pneumococcal antibody titer in the atorvastatin group compared to the placebo group (2-way ANOVA, p = .0177). CONCLUSIONS:Atorvastatin enhances antigen-specific primary humoral immune response to a T cell-independent pneumonia vaccination. Pending confirmation by larger cohort studies of target populations, peri-vaccination conventional doses of statins can become a novel adjuvant for poorly-immunogenic polysaccharide-based vaccines. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02097589.
Authors: Shuren Li; Robert Dudczak; Elisabeth Koller; Mehrdad Baghestanian; Minoo Ghannadan; Erich Minar; Christian Pirich; Peter Angelberger; Irene Virgolini; Mei Li; Peter Valent Journal: Eur J Clin Pharmacol Date: 2003-09-10 Impact factor: 2.953
Authors: Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil Journal: Nature Date: 2002-11-07 Impact factor: 49.962
Authors: D R Feikin; A Schuchat; M Kolczak; N L Barrett; L H Harrison; L Lefkowitz; A McGeer; M M Farley; D J Vugia; C Lexau; K R Stefonek; J E Patterson; J H Jorgensen Journal: Am J Public Health Date: 2000-02 Impact factor: 9.308
Authors: Lisa A Jackson; Kathleen M Neuzil; Onchee Yu; Patti Benson; William E Barlow; Annette L Adams; Christi A Hanson; Lisa D Mahoney; David K Shay; William W Thompson Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Thomas Fehr; Christian Kahlert; Walter Fierz; Helen I Joller-Jemelka; Walter F Riesen; Hans Rickli; Rudolf P Wüthrich; Peter Ammann Journal: Atherosclerosis Date: 2004-07 Impact factor: 5.162
Authors: Mathew Sebastian; Chu J Hsiao; Hunter S Futch; Robert S Eisinger; Leanne Dumeny; Seema Patel; Mesfin Gobena; Divya S Katikaneni; Joel Cohen; Anne-Marie Carpenter; Lisa Spiryda; Coy D Heldermon; Lei Jin; Mark L Brantly Journal: JCI Insight Date: 2020-05-07